Jamjoom Pharmaceuticals Factory Company (4015) Fair Value & Analysis
Healthcare · SA · Market cap 9.7B SAR
Fair value as of: Jul 31, 2026
From 24 valuation models · updated today
Share price −11.7% over the past month.
What matters now
- A high-quality business (quality 71/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The model range is unusually wide (75.70 SAR to 209.85 SAR). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (12 months)
12‑month range 125.99 SAR – 163.60 SAR · fair‑value band 75.70 SAR – 209.85 SAR · the 136.80 SAR price screens above the 110.36 SAR fair value. As of Jul 31, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Jamjoom Pharmaceuticals Factory Company (4015) currently trades at 136.80 SAR, while our model-based Fair Value estimate is 110.36 SAR, implying the stock looks roughly 19.3% overvalued today. We read business quality at 71/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Jamjoom Pharmaceuticals Factory Company generated revenue of 1.6B SAR at a net margin of 30.5%. Revenue grew 12.4% year over year. It earns a return on equity of 27.0%. The balance sheet holds a net cash position of 260M SAR. Fundamentals as of Jul 31, 2026
Our scenario range runs from 75.70 SAR (bear case) to 209.85 SAR (bull case); at 136.80 SAR, the current price sits within that range. The share trades about 17% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -54% fair-value upside, at -19%, 4015 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 31, 2026. TTM = trailing twelve months.
Quality Score breakdown
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Jamjoom Pharmaceuticals Factory Company, together with its subsidiaries, engages in the manufacture and distribution of pharmaceutical and consumer products in the Kingdom of Saudi Arabia, Gulf, Iraq, Egypt, North Africa, and internationally.
Full company description
Jamjoom Pharmaceuticals Factory Company, together with its subsidiaries, engages in the manufacture and distribution of pharmaceutical and consumer products in the Kingdom of Saudi Arabia, Gulf, Iraq, Egypt, North Africa, and internationally. It provides human medicines; nutraceuticals; antibiotics; general analgesics; medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, and ulcer and acidity; treatment of various skin infections and cancer diseases; and eye drops, and ointments and cosmeceuticals. The company also offers ophthalmic solutions, dermatology products, cardiovascular health, consumer health, respiratory health, gastrointestinal health, endocrinology and diabetes care, central nervous system, and pain and inflammation pharmaceutical products. Jamjoom Pharmaceuticals Factory Company was founded in 1994 and is based in Jeddah, the Kingdom of Saudi Arabia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Jamjoom Pharmaceuticals Factory Company reported revenue of 1.5B SAR in FY2025 versus 736M SAR in FY2021, a compound +19.5%/yr. Reported net income was 464M SAR in FY2025, compounding +28.4%/yr from FY2021.
Is 4015 fairly valued? → Check now
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥49.36 | ¥30.99 | -37% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,464 | ₹1,504 | -66% |
| PharmaEssentia Corporation 6446 | 1,095 TWD | 365.87 TWD | -67% |
| Cipla Limited CIPLA | ₹1,401 | ₹592.37 | -58% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,098 | ₹507.31 | -54% |
| Lupin Limited LUPIN | ₹2,268 | ₹2,697 | +19% |
| Mankind Pharma Limited MANKIND | ₹2,336 | ₹1,068 | -54% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,291 | ₹1,053 | -18% |
Compare Jamjoom Pharmaceuticals Factory Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Jamjoom Pharmaceuticals Factory Company (4015) overvalued or undervalued?
What is the fair value of 4015?
What is the quality score of 4015?
What is the revenue of Jamjoom Pharmaceuticals Factory Company (4015)?
What is the net profit margin of 4015?
Does Jamjoom Pharmaceuticals Factory Company pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Jamjoom Pharmaceuticals Factory Company and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.